Pfizer (NYSE:PFE) has received mixed analyst ratings over the past three months, with 8 analysts offering varied opinions. The average 12-month price target is $41.25, up 12.49% from the previous $36.67. Analysts from firms including Cantor Fitzgerald, TD Cowen, Truist Securities, UBS, and Barclays have maintained or lowered their price targets, with ratings ranging from 'Overweight' to 'Neutral'. Pfizer's financials show a revenue decline of -41.55% as of September 30, 2023, a net margin of -18.0%, ROE of -2.43%, ROA of -1.09%, and a debt-to-equity ratio of 0.66.